Sitagliptin-Associated Weight Change
Sitagliptin is associated with, at most, a small average reduction in body weight in overweight or obese adults with type 2 diabetes. [1]
Evidence From Randomized Trials and Meta-Analysis
A systematic review and meta-analysis of 18 randomized controlled trials (n=2009) found that sitagliptin was associated with statistically significant weight loss versus placebo in both sitagliptin-treated and sitagliptin-plus-metformin-treated groups. [1]
Magnitude of Expected Weight Change
Mean difference for body weight change favored sitagliptin versus placebo as follows:
- Sitagliptin-treated groups: MD −0.99 kg (95% CI −1.87 to −0.12). [1]
- Sitagliptin-plus-metformin-treated groups: MD −1.09 kg (95% CI −1.69 to −0.49). [1]
Time Course
The meta-analysis concluded that weight reduction may require treatment duration longer than 6 months. [1]
Clinical Interpretation
The effect size reported in trials is small on average and is consistent with limited weight-loss efficacy compared with glucose-lowering agents designed for weight reduction. [1]
Practical Clinical Considerations
Weight change monitoring is appropriate when sitagliptin is used for glycemic control in patients who are overweight or obese, because the observed average reduction is modest and may not be clinically meaningful for all individuals. [1]